- Home
- CVM vs RLYB Comparison
CVM vs RLYB Comparison
Compare CVM & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVM
- RLYB
- Stock Information
- Founded
- CVM 1983
- RLYB 2018
- Country
- CVM United States
- RLYB United States
- Employees
- CVM N/A
- RLYB N/A
- Industry
- CVM Biotechnology: Biological Products (No Diagnostic Substances)
- RLYB Biotechnology: Pharmaceutical Preparations
- Sector
- CVM Health Care
- RLYB Health Care
- Exchange
- CVM Nasdaq
- RLYB Nasdaq
- Market Cap
- CVM 40.1M
- RLYB 45.2M
- IPO Year
- CVM 1987
- RLYB 2021
- Fundamental
- Price
- CVM $0.62
- RLYB $1.00
- Analyst Decision
- CVM
- RLYB Buy
- Analyst Count
- CVM 0
- RLYB 6
- Target Price
- CVM N/A
- RLYB $8.10
- AVG Volume (30 Days)
- CVM 469.2K
- RLYB 96.2K
- Earning Date
- CVM 02-12-2025
- RLYB 11-07-2024
- Dividend Yield
- CVM N/A
- RLYB N/A
- EPS Growth
- CVM N/A
- RLYB N/A
- EPS
- CVM N/A
- RLYB N/A
- Revenue
- CVM N/A
- RLYB $598,000.00
- Revenue This Year
- CVM N/A
- RLYB N/A
- Revenue Next Year
- CVM $3,412.81
- RLYB N/A
- P/E Ratio
- CVM N/A
- RLYB N/A
- Revenue Growth
- CVM N/A
- RLYB N/A
- 52 Week Low
- CVM $0.49
- RLYB $0.95
- 52 Week High
- CVM $3.23
- RLYB $3.46
- Technical
- Relative Strength Index (RSI)
- CVM 45.83
- RLYB 43.40
- Support Level
- CVM $0.60
- RLYB $1.00
- Resistance Level
- CVM $0.78
- RLYB $1.24
- Average True Range (ATR)
- CVM 0.09
- RLYB 0.08
- MACD
- CVM 0.02
- RLYB -0.01
- Stochastic Oscillator
- CVM 45.66
- RLYB 7.59
About CVM Cel-Sci Corporation
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company's core capabilities that include are drug discovery, research, development and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.